Health, Digital Health, mHealth, Digital Pharma, hcsm latest trends and news (in English)
53.7K views | +1 today
Health, Digital Health, mHealth, Digital Pharma, hcsm latest trends and news (in English)
Your new post is loading...
Your new post is loading...
Rescooped by Celine Sportisse from Healthcare and Technology news!

Technology is changing healthcare

Technology is changing healthcare | Health, Digital Health, mHealth, Digital Pharma, hcsm latest trends and news (in English) |
Personalised medicine is becoming a reality.

Just as high speed broadband and smart phones have empowered consumers in retailing and banking there is talk of the same happening for patients in medicine.

All this offers exciting opportunities for BBC News. Our health news offering can reflect and benefit from the big leaps forward in the world of medical technology.

The business of health in the UK is flourishing. The UK is now the top destination for fundraising by life sciences companies, ahead of Switzerland, France and Germany. A report for the BioIndustry Association showed there were 460 biotech drugs under development in the UK, up 15% on the previous year. The so-called "golden triangle" of London, Oxford and Cambridge has the largest concentration of life science brainpower of any leading economy - with rival academic clusters geographically more widely spread.

As biotech companies grow, so too do start-up ventures creating apps to help people monitor everything from pulse to sleep patterns. NHS England has launched an apps library to help people find appropriate programmes to monitor their health. Opportunities for patients and app developers are opening up rapidly.
iOS8 screens News has a part to play in explaining how health technology is developing

Health monitoring in the home, using wristbands, laptops and smartphones, offers the potential to change the face of healthcare. Sir Bruce Keogh, medical director for NHS England, told me in an interview that "the hospital of the future is in the home". Sir Bruce raised the possibility that in a couple of decades time people will wonder why previous generations paid for large buildings with beds in them.

BBC News has a part to play helping people chart their way through this fast-changing but potentially confusing world. Explaining what's available, perhaps even providing health apps, opens up interesting possibilities. Just as genomics is developing a new world of tailored treatments rather than single drugs or therapies for patients of cancer or other diseases, so consumers may expect more individually relevant health news.

The NHS is looking to make better use of constrained resources at a time of rising demand for care because of the growing and ageing population. There are major challenges as budgets are stretched. Technology is no panacea but the NHS sees it as a potential source of greater efficiency across the service.

Consumer interest in health news is always high. So too technology. With the two fields converging, the appetite for information can only intensify. The BBC health offering can play an important part and rise to the challenge.

Via Technical Dr. Inc.
Jakarta Web Developer's curator insight, February 6, 2015 7:49 AM

Web Design & Development

be social:

SageRave of Get Custom Content's curator insight, February 20, 2015 1:59 PM

Will our grandchildren have "health chips", inserted at birth, instead of immunization records? Will they monitor smokers after doctors demand they stop smoking? Will they use any evidence, on your chip, against you in a court of law? I wouldn't want that much technology between me and my pleasures,, but I'd love to communicate with a doctor, without having to go to the office!

talulahmay's curator insight, April 25, 2015 3:13 AM

Rescooped by Celine Sportisse from Healthcare and Technology news!

Google, Biogen will use wearable sensors to study multiple sclerosis

Google, Biogen will use wearable sensors to study multiple sclerosis | Health, Digital Health, mHealth, Digital Pharma, hcsm latest trends and news (in English) |

Biogen Idec has partnered with Google X, Google’s business unit for long-term “moonshot” projects, to study outside factors that might contribute to the progression of multiple sclerosis (MS), according to a report from Bloomberg.

Google and Biogen will use sensors, software, and data analysis tools to collect and analyze data from people who have MS. The companies aim to explore why MS progresses differently in each patient.

Bloomberg pointed out that Biogen has used digital tools for its disease research in the past. Last month, Biogen announced that it was using Fitbit activity trackers to gather data from people who have MS. It gave 250 Fitbit bands to participants to track their level of activity and sleep patterns. Last summer, the pharma company worked with Cleveland Clinic to develop an iPad app to assess MS progression. 

Via nrip, pcorral3432, Technical Dr. Inc.
Farid Mheir's curator insight, January 29, 2015 7:43 AM

Companies should do this more often: experiment with new technologies - cloud, analytics, wearables, etc. - to explore new business opportunities with minimal investments. All technology companies do it yet few in the traditional environments seam to grab the opportunity. Why?

ChemaCepeda's curator insight, February 2, 2015 1:08 PM

Cuantificación personal, wearables y big data al servicio de la captura y análisis de información para el estudio de la progresión de enfermedades como la esclerosis múltiple.

Nadine Quinn's curator insight, February 18, 2015 10:38 AM

ajouter votre aperçu ...

Rescooped by Celine Sportisse from Healthcare and Technology news!

Digital Health: Will Pharma Follow or Lead?

Digital Health: Will Pharma Follow or Lead? | Health, Digital Health, mHealth, Digital Pharma, hcsm latest trends and news (in English) |
Time to step up or step out of the way?

The digital health movement is growing rapidly. Almost everyday we hear of new technology, apps and ideas that bring the promise of improved medical care, health and wellness. From hand-held ultrasound devices to smart phone arrhythmia monitoring, the digital health movement isn’t only about expensive pedometers and the ‘gym elite’ but about key areas in health and wellness that will have a direct impact on medical care. Pharma–for better or worse–has a seat at this table.

Concept and Illustration: Peter Zamiska

Yet there seems to be a bit of a disconnect between pharma and many of the innovations that are emerging. Perhaps it’s the very nature of these innovations that conflicts with the conservative pharmaceutical industry. Perhaps it’s still a period of ‘watchful waiting’. Or even, it could be yesterday’s brand managers, sales reps and administrators who, while caressing the piles of pills that define an industry, are just missing what many define as the next revolution since the personal computer.

Whatever the case, there are many compelling reasons for pharma to embrace digital health. If not for today, certainly in the not so distant future.

The future of medical practice and pharmaceutical selling

The pressures on the practice of medicine are numerous. From healthcare reform to the tsunami of clinical information and data, today’s providers are looking for ways to care and to cope. Technology is an essential part of the solution. And digital health is a central part of this equation. The touch points for pharma are numerous and represent areas for engagement and support. On demand information and analytics will shift the focus from bed side ‘rote memorization’ to “augmented digital expression” where a differential diagnosis and interventions come with the aid of a hand-held computer screen. Further, the looming role of the electronic medical record will also set into motion a transformation from paper to electrons will catalyze the digital health movement and accelerate adoption. Many of these changes are happening now as a new generation of medical students begin to use their smart phones at bedside as a diagnostic and therapeutic tool with the same zeal as yesterday’s physicians who clung to their stethoscopes as validation of their clinical acumen.

The traditional role of the sales rep must also change. The consultative nature of the brand detail will shift in parallel with the technology-driven changes in practice. Pressing the flesh will transform to clinking a link and clinicians will adopt the conventions of today’s consumers and seek information in a controlled on-line setting. But perhaps more importantly, the days of typical case studies and efficacy charts will be replaced with a richer and more compelling presentation that are consistent with what this ‘techno’ generational will simply expect. And the experts themselves will change too–the standard practice of expert professorial engagement and peer to peer influence may be enhanced by none other than IBM IBM +1.92%‘s Watson and other ‘electronic’ thought-leaders.

Patients and caregivers will play an important role in the evolution of healthcare and digital health. The emergence of “citizen scientists” who are empowered by increasingly focused and filtered information will act–alone and with like-minded people–to take greater control of care. Self-advocacy will change ‘population-based’ treatment guidelines to more personalized care. And the pandering “ask your doctor” headlines of DTC advertisements will shift to data-based claims that empower the patient and make a much stronger and direct link between the pharmaceutical industry and the true end-user, not the physician.

Maybe it’s digital narcolepsy?

Whatever the cause, pharma needs to take notice. The cases studies and talking points that drive a traditional brand detail must be rethought and redefined in the context of tomorrow’s clinical reality. A reality that’s actually happening today.

Via Technical Dr. Inc.
Rescooped by Celine Sportisse from!

Inside the 'iWatch': The technology Apple is looking at for your Wrist

Inside the 'iWatch': The technology Apple is looking at for your Wrist | Health, Digital Health, mHealth, Digital Pharma, hcsm latest trends and news (in English) |

Apple's anticipated entry to the wearable devices market has taken on near-mythical status, with rumors reaching every corner of the technology map. AppleInsider has rounded up some of the technologies most likely to find their way into the still-unannounced "iWatch."



GT Advanced Technologies' ASF sapphire furnace.
Source: GT Advanced

Apple's interest: A $578 million deal with sapphire equipment maker GT Advanced Technologies to open and operate a massive commercial sapphire plant in Arizona.

Much has been made of Apple's agreement GT Advanced Technologies. Many believe the new jointly-operated facility in Arizona will produce display covers to replace the Gorilla Glass currently used in the iPhone and iPad; some think the crystals will be used in an iWatch, while still others believe that Apple simply needs more sapphire for its camera lenses and Touch ID housings.

If sapphire is to be used as a main component of an Apple device, the iWatch is its most likely target. High-end watch companies have long used sapphire to cover the faces of their timepieces because of its scratch resistance, but — as anyone who has dropped a sapphire-covered watch can attest — the material is prone to shattering, making it far better suited for a device that's constantly strapped to a person rather than hanging loosely in their hands.


A number of cast Liquidmetal casings for mobile phones | Source: Liquidmetal

Apple's interest: A $20 million contract for exclusive rights to use Liquidmetal in consumer electronics and a number of manufacturing patents related to the material. That agreement was re-upped through February 2015 earlier this week.

Liquidmetal is an amorphous alloys — essentially, metallic glass — that is much lighter, harder, and more flexible than metals traditionally used in electronics manufacturing. Parts made of Liquidmetal could "snap back" from deformations that might cause permanent bends or dents in other metals, such as Apple's omnipresent aluminum, and it's extremely scratch-resistant.

Liquidmetal is difficult to work with, however. Apple famously tested its viability by using it to make the SIM ejector tool included with the iPhone 3GS, but Liquidmetal's inventor predicted in 2012 that at least two to four years of further refinement in manufacturing processes was necessary before it could be commercially viable on a large scale.

Complicating Liquidmetal's possible appearance in Apple's iWatch is a deal with Switzerland's Swatch group that granted the horologists exclusive use of Liquidmetal in watches.



Samsung Mobile Display showing off a flexible display at CES 2011. Source:

Apple's interest: Apple has a number of OLED-related patents to its name, including dynamic brightness adjustment and improved power efficiency. The company also hired away a senior OLED researcher from LG Display.

OLED — or organic light-emitting diode — displays are a new type of display in which each pixel is made of an organic compound that emits light when electrical current is passed through it. Because of this design, OLED panels don't require a backlight, making them thinner and lighter than traditional LCD-based panels and adding the potential to be folded or curved.

While many Apple watchers previously expected the iWatch to ship with a more traditional LCD panel, the tide of opinion has shifted in recent months in favor of OLED. The inclusion of a flexible OLED would allow for a more form-fitting design in which the screen could curve with the contours of the wearer's wrist, rather than sitting flat on the top.

From the outside, Apple has long seemed apathetic toward OLEDs. Former CEO Steve Jobs is thought to have disliked the technology, and current chief Tim Cook panned OLED earlier this year, saying that the displays showed "awful" color saturation.

"If you ever buy anything online and really want to know what he color is, as many people do, you should really think twice before you depend on the color from an OLED display," he said.


A similar micro LED array displayed by Taiwanese researchers

Apple's interest: Acquired micro-LED display maker LuxVue Technologies earlier this month for an unknown price.

Micro LEDs are essentially exactly what they sound like: very small LEDs. The technology that enables their miniaturization also plays a part in lowering power consumption and increasing brightness, with the combination placing micro LED arrays in direct competition with OLEDs.

This is a relatively new technology, however; Apple's acquisition of secretive LuxVue is likely to have given micro LEDs more exposure the day it was uncovered than the technology has received since its invention. Despite a number of high-profile backers — and their rumored inclusion in Google's next-generation Glass headset — micro LEDs have yet to find their way into shipping consumer device.

Still, there is reason to believe that Apple may have chosen the micro LED route. At least one of LuxVue's patents covers the manufacturing of a curved micro LED array, which could replace the flexible AMOLED display Apple is thought to have targeted.


Apple has made a massive investment in semiconductor technology in recent years, and the iWatch is likely to put those advancements front-and-center. While the iPhone is a technologically impressive piece of kit, the iWatch would have to be a miniaturization tour de force in order to live up to the rumors surrounding its capabilities.

Apple began its semiconductor roadshow in 2008 with the purchase of P.A. Semi, a power-efficient fabless semiconductor design firm working on PowerPC-based chips. Later, in 2010, they purchased Intrinsity, an ARM-focused studio that is thought to have contributed to the development of the A-series processors.
Apple has spent nearly $1 billion on semiconductor technology firms — that we know of.
Last August, Apple acquired Passif Semiconductor, a company that develops ultra-low-power communications chips. The company has also been seen snapping up senior RF engineers from Broadcom, sparking rumors of a new in-house baseband team.

Finally, last November, Apple picked up Israeli firm PrimeSense for a rumored $360 million, pushing their total investment in semiconductor technology up toward $1 billion. Taken together, the sheer volum of chip design talent and intellectual property now in-house in Cupertino is staggering — any iWatch introduction is likely to bring along with it a similarly-impressive display of silicon engineering.

That probably, won't include noninvasive blood glucose monitoring or three-dimensional mapping, though. Apple is more likely to put its considerable resources to bear on more mundane, but still difficult tasks — like integrating an application processor, baseband, and wireless communications controller in a single, smaller, less power-hungry chip.

Via TechinBiz, dbtmobile, Bart Collet
♥ princess leia ♥'s curator insight, January 25, 2015 2:40 PM

The future is waiting for us